Affordable Access

deepdyve-link
Publisher Website

Depression and substance use disorders: Clinical comorbidity and shared neurobiology.

Authors
  • Calarco, Cali A1
  • Lobo, Mary Kay2
  • 1 Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, United States. , (United States)
  • 2 Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: [email protected] , (United States)
Type
Published Article
Journal
International review of neurobiology
Publication Date
Jan 01, 2021
Volume
157
Pages
245–309
Identifiers
DOI: 10.1016/bs.irn.2020.09.004
PMID: 33648671
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Mood disorders, including major depressive disorder (MDD), are the most prevalent psychiatric illnesses, and pose an incredible burden to society, both in terms of disability and in terms of costs associated with medical care and lost work time. MDD has extremely high rates of comorbidity with substance use disorders (SUD) as many of the same neurobiological circuits and molecular mechanisms regulate the reward pathways disrupted in both conditions. MDD may induce SUDs, SUD may contribute to MDD development, or underlying vulnerabilities and common life experience may confer risk to developing both conditions. In this chapter we explore theories of MDD and SUD comorbidity, the neurobiological underpinnings of depression, overlapping cellular and molecular pathways for both conditions, and current treatment approaches for these comorbid conditions. Copyright © 2021 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times